<DOC>
	<DOC>NCT00935662</DOC>
	<brief_summary>The primary objective for this study is to assess the safety and tolerability of AZD8329 when given as a single dose in increasing dose strength, and also to identify the highest tolerated dose for future studies.</brief_summary>
	<brief_title>A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Have a body mass index between 19 and 30 kg/m2 and weigh at least 50 kg Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the result of the study, or the subjectÂ´s ability to participate Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>First time in man</keyword>
	<keyword>Safety study</keyword>
	<keyword>AZD8329</keyword>
</DOC>